Abbott's revenue growth accelerated to 14.5% year over year in 2026Q3 from roughly 4% in 2024, and gross margin expanded from about 51% to 57.1%, though this growth appears heavily acquisition-driven given the $19.8B net acquisition outflow in 2026Q1.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth reached 14.5% in 2026Q3 and gross margin improved to 57.1%, yet net margin compressed from 15.5% in 2025Q4 to 7.1% as operating expenses outpaced gross profit growth.
The successful integration of Exact Sciences is expected to significantly boost Abbott's diagnostics business and overall growth trajectory.
Analysts project mid-teens growth for Cologuard, supported by a substantial addressable market.
New electrophysiology products like Volt PFA and TactiFlex Duo are receiving extremely favorable physician feedback, indicating potential for accelerated growth.
The Nutrition segment has faced declines due to incomplete pricing pass-through at retail, posing a risk to revenue.
The Exact Sciences acquisition is expected to dilute EPS, impacting earnings through 2026 and 2027 before becoming accretive.
Abbott faces litigation risks, including a recent $70 million jury award related to infant formula safety, with hundreds of similar cases pending.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 21, 2026 | $1.42+0.0% vs $1.42 | $13.0B+0.2% vs $13.0B |
Q3 2026 Jul 16, 2026 | $1.31+2.3% vs $1.28 | $12.6B+0.6% vs $12.5B |
Q2 2026 Apr 16, 2026 | $1.15+0.9% vs $1.14 | $11.2B+1.5% vs $11.0B |
Q1 2026 Jan 22, 2026 | $1.50+0.0% vs $1.50 | $11.5B-2.9% vs $11.8B |
Hospitals reorder syringes, sensors, and implants whether the economy booms or stalls, and three device makers turn that habit into payouts that grow every year.
I present 69 Dividend Champions with Dividend Safety scores of 8+ and rank them using my 9F Quality Scores system. Twenty-two featured Dividend Champions are undervalued, while 21 are overvalued. Forty-nine have quality scores ≥ 7.0, indicating high quality. Top candidates by style: BRO and BMI for growth; BRO, BMI, and RGLD (below $262) for total return; CTBI for income; CAT for past performance.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Investment newsletters' favorite Dividend Aristocrat stocks
Benchmark ABT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Abbott Laboratories (ABT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $109.93 | $191.48B | 29.55 | 5.67% | 14.72% | 12.96% | 2.14% | |
| $101.80 | $130.7B | 27.29 | 8.43% | 13.93% | 10.51% | 2.78% | |
| $42.75 | $63.54B | 22.04 | 19.87% | 16.56% | 13.74% | — | |
| $211.88 | $58.38B | 36.34 | 8.23% | 4.52% | 3.79% | 1.97% | |
| $25.79 | $13.32B | -14.74 | 5.72% | -6.23% | -11.67% | 2.63% | |
| $102.14 | $58.81B | 55.81 | 11.55% | 15.43% | 9.66% | — |
Abbott Laboratories (ABT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Abbott Laboratories (ABT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 21, 2026·SEC
Oct 21, 2026·SEC
Jul 16, 2026·SEC
Get notified when ABT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Abbott Laboratories (ABT) stock FAQ — growth, dividends, profitability & financials explained
Abbott Laboratories (ABT) reported $48.23B in revenue over the trailing twelve months. Revenue was $44.33B in fiscal year 2025. That is 302% more than the $11.01B of fiscal year 1996.
Abbott Laboratories (ABT) grew revenue by 5.7% in fiscal year 2025, compared with the prior fiscal year.
Yes. Abbott Laboratories (ABT) earned $4.70B in net income over the trailing twelve months (a 9.7% net margin).
Yes. Abbott Laboratories (ABT) pays a dividend that yields 2.14% at the current price, a moderate yield.
Abbott Laboratories (ABT) had a return on equity (ROE) of 13.0% in fiscal year 2025. That is in line with the market's typical 10-15%.
Abbott Laboratories (ABT) generated $7.65B in free cash flow over the trailing twelve months.
